MICHAEL MCINTYRE
EDITOR’S LETTER
Rewriting the Code of Life
Dear Readers,
Biologyisnolongerdestiny;itisadesignspace.Fordecades,biotechnologywasdefinedbywhatwe coulddiscoverunderamicroscope.Today,itisdefinedbywhatwecanimaginebeyondit.Weare standingattheprecipiceofanewerawherethelinebetweentechnologyandbiologyisnotjustblurring; itisdisappearing.Wearenolongerjusttreatingsymptomswithpills;wearerewritingthefundamental instructionsofhealthitself.Thistransformationrequiresaspecialkindofvisionary,leaderswhoseethe humanbodynotasafixedmachine,butasadynamicecosystemwaitingtobeoptimized.Itisthisspirit ofboundlessinnovationthatwecelebrateinourlatestedition,TheMostInfluentialLeadersShaping theBiotechIndustryin2025.
LeadingthischargeonourcoverisMichaelMcIntyre,theFounderandCEOofARRCLED.While muchofthewellnessworldfocusesonchemicalinterventions,Michaelhasturnedhisattentiontothe mostfundamentalforceintheuniverse:light.
Operatingontheboldandstraightforwardmissionof“SickPersonIn,HealthyPersonOut,”heis pioneeringthefieldof“bioenergeticarchitecture.”Toviewhisworkmerelyasredlighttherapywouldbe amistake;throughhisgroundbreakingElysiumDevice,heutilizeswhole-bodyphotobiomodulation (PBMt)totransmitcomplexinformationpatternsdeepintothebody’squantumfield.Bycombining dose-optimizedwavelengthswithspecificfrequencies,Michaelisprovingthatwecandomorethanjust repairthebody—wecancommunicatewithit,upgradinghumanpotentialfromtheinsideout.
JoiningMichaelinthisgroundbreakingissueisagroupofpioneerswhoarerewritingtherulesoftheir respectivefields.WeareproudtofeaturethestrategicinsightsofJenniferKirk,ChiefExecutiveOfficer ofExubrionTherapeutics;theoperationalleadershipofMiriamCho,PresidentandChiefPharmacy OfficerofMACRx;thediagnosticinnovationsofMichaelRasche,CEOofDiademSpA;andthe investmentforesightofDr.LeenKawas,ManagingGeneralPartnerofPropelBioPartners.
Thestorieswithinthesepagesaremorethanjustbusinessprofiles;theyareglimpsesintoafuturewhere “incurable”isawordofthepast.Theseleadersarenotjustshapinganindustry;theyareshapingthe futureofourspecies.
HappyReading!
PANKAJ GHOLAP
PROJECT EDITOR
Michael McIntyre
MCINTYRE MICHAEL
Illuminating the Future of Health with Light and Quantum Fields COVER / STORY
Inthemodernworldofwellness,weoften
focusonthematerialaspectsofhealth.We discusssupplements,surgeries,and pharmaceuticals—interventionsdesignedtofixor repairourphysicalbodies.Butwhatifourbodies arenotthecoreofourbeing?Whatiftheyare simplybiologicalmanifestationsofdeeper,more fundamentalinstructions?Andwhatifateamof innovators,ledbyauniquecombinationofelite athletes,researchscientists,andspiritualexperts, hasdiscoveredhowtorewritethosefundamental instructionsusingthemostbasicforceinthe universe: light?
Thisistheworldof MichaelMcIntyre,the founderandCEOofARRCLED,andhispartner SonoeFujita.ReferringtoARRCLEDasa “red light therapy” businessislikecallingaparticle acceleratorachild’stoy Theirworktranscends conventionalwellness;itfocusesonbioenergetic architecture.Theirmissionisasboldasitis straightforward: “Sick Person In, Healthy Person Out.”
ARRCLEDandARRCBIOTECHutilizea technologyknownaswhole-body photobiomodulation(PBMt),whichhasbecomea trustedresourceforsomeofthemostdemanding organizationsglobally Thistechnologyisusedby everybranchoftheU.S.military,worldleaders,and elitesportsteamslikethePhiladelphiaEaglesand theTampaBayBuccaneers.However,toviewthis technologymerelyasatoolforperformance enhancementwouldoverlooktheprofounddepthof theirvision.
TheQuantumBlueprint
Michaelisaformercollegiatefootballplayerand elitepowerlifterwithabackgroundinmarketing researchandbiochemistry.Hebelievesthatthe foundationofhisworkarisesfromhisownpractices andtheexperienceshehasgainedbyobserving mastersinQiGong,Buddhism,andKriyaYoga meditationperformwhatmanywouldconsider miraculousfeats.Thisexposurehasfueledhis passionforexpandingconsciousnessandenhancing individualhealth.Hisworkaimstopioneerthenext frontierofmedicinebyexploringhowtonotonly bendlightbutalsouseittocreateanewnarrative forhumanpotential.
AtthecoreoftheARRCLEDphilosophyisa paradigm-shiftingunderstandingofhealth. Thebeliefisthatalldis-easebeginsnotatthe cellularlevel,butratherasdistorted informationpatternsinthequantumfield.
“Wetendtoseediseaseandinjuryasoutcomes ofeitherchemicalorphysiologicaldamagethat occursinlineartime,”heexplains.“Inthe quantumfield,everythinghappensbeyondtime andspace.Thisfieldisdrivenbyintent,which isinstantaneous.”
“Ourfocusnowisonhowwemayamplify intentandimprovecoherenceusingtechnology suchasTheElysiumDevice,”Michael clarifies.“Themorecoherentthefield,the moreoptimalthebiologicalexpression.”Their worksuggeststhattheanswerisyes.“Inthe quantumrealm,weobserveaninstantaneous benefitfromElysiumduringremotesessions. Thismeansthatweseethisincredible technologyinstigateanimmediate physiologicalresponseassoonasweflipthe switch.YoumightbeinBoston,andthe ElysiumStargatecouldbeinCalifornia. Throughourquantumresonanceportal,wecan elicitaninstantaneousphysiologicalreactionin youwhileyou’resittingatyourdeskin Boston.”
TheOriginSignal
Everyrevolutionbeginswithasignal—a whisperfromanunexpectedsourcethathintsat amuchlargertruth.ForMichael,thatsignal didnotcomefromauniversitylabbutfromthe frontlinesofthespaindustry.Itwas2006 whenhewassupplyingaestheticianswithLED facialpanels.However,hisclients,drivenby intuitionandadesiretohelp,beganusingthese panelsformorethanjustskincare.
“They would use the panels on diabetic ulcers, pain, injuries, and more,” Michaelrecalls.
“Every couple of weeks, one of them would call me and say, ‘Mike, do you know what this is doing now?’” Thesecalls providedreal-worldevidencethatthelight wasinteractingwithbiologyinwaysthe mainstreamdidnotfullyunderstand.
Thiswasthesignalthatpropelledhimintoa decadeofexperimentation.Hebeganworking inthefieldofphotobiomodulationin2007, andby2015,hewasreadytobuildhisown system,foundingARRCLEDtocreatehisfirst whole-bodydevice.
Eveninthoseearlydays,hisvisionwas alreadylight-yearsaheadoftheindustry.
“In 2015, we were already working outside the boundaries of red light therapy,” Michael notes. “We were combining green light, which I knew was doing more than research showed, and using wavelengths as carriers for frequencies.” Hewasn’tjustshininglights;he wasexploringtheconceptoflightasan informationdeliverysystem.Thisfoundational insightmarkedthefirststepinengineeringa technologythatwoulddomorethanjustheal thebody;itwouldcommunicatewithit.
DeconstructingLight:TheARRCBlueprint
Toappreciatetheadvancementsmade byARRCLED,itisessentialtofirst graspthecurrentlimitationsofthe conversationsurroundingit. “Red Light Therapy is a buzzword,” headmits,with ahintoffrustration.
“My biggest challenge is the hype and the false claims surrounding it. Many people are exploiting this trend with misleading assertions, and it worries me that this could harm a powerful new industry ARRC is not just a red light company; our systems are genuine energy devices.”
Hisfocusisonphotobiomodulation,the modificationofbiologicalprocessesthrough light.However,thisisjustthesurface.AtARRC, lightwavesservebothasthetherapyandthe deliverymechanism. “At ARRC, we utilize light waves as carriers for frequency and quantum field information blueprints,” heexplains.This innovativeapproachdefinestheirwork. Whilethesystemsprovidetherecognized benefitsofsixdistinct,dose-optimized wavelengthsoflight(rangingfrompainreducingredtoendorphin-boostinggreen),they alsousethesebeamstotransmitcomplex informationpatternsdeepintothebody’s energeticfield.
In2018,heengagedDr.MichaelHamblin, aleadingresearcherinphotobiomodulation fromMITandHarvard,tohelpdevelopthe class-leadingATPlightingsystem.
Thissystemisasophisticated,multi-layeredsymphonyof energeticintervention:
● TheLightsbuildfoundationalwellness,stimulating cellularregenerationandotherbiologicalcascades.
● TheFrequencies,carriedonthelightwaves,actlikea “scalpelonpathogens,”capableoftargetingspecificissues withimmenseprecision.
● TheInformationPatternsarethe“quantumfield informationblueprints”thatprovidethebodywithanew setofinstructionsforfuturehealthandoptimalfunction.
● TheScanner,thelatestinnovation,activelyscansthe bodyforstressandenergeticanomaliesduringasession anddeliversmicro-pulsesofcorrectiveenergyinrealtime.
“No one in the world is doing this to the extent that ARRC LED is,” Michaelassertswithquietconfidence. “The technology we’ve developed will eventually become mainstream, which is exciting. We are already working on the next levels of technology; our focus is always forward, never backward.”
Headds, “This is why when people get out of our beds, they not only feel significantly different, but you can also see the energetic change in their faces.” Thisvisibletransformation, thisnewfound “live energy” inaperson’sexpression,servesas immediate,tangibleevidenceoftechnologyfunctioningata levelwellbeyondsuperficialeffects.
ProofofConcept:ValidatedbytheElite
Thefirstadoptersoftrulyrevolutionary technologyoftencomefromtheextremesof humanperformance.ARRCLED’svalidation beganwitheliteanddemandingclients, includingtheUSMilitaryandthe PhiladelphiaEagles,whowontheSuper Bowlin2015,asnotedbyMichael.
Whiletheseorganizationsaretypically secretiveabouttheircompetitiveadvantages, theimpactofthistechnologyisclear.Coach TomNewman,whoworkswithprofessional baseballplayers,hasconductedresearch showingthatpropitcherscansignificantly extendtheirseasonsbyusingtheARRC chambers.Michaelexplainsthattheyarenot merelytreatingaspecificinjury “We don’t treat their arm so they can pitch longer,” he clarifies. “We change the bioenergetics of their body so that everything improves.”
Thisisanessentialdistinction.Thetechnology isnotjustatargetedrepairtool;itisa system-wideupgrade.Thisiswhyits benefitsareuniversal. “The benefits to a professional athlete also extend to an elderly person walking up stairs, a weekend warrior, and an executive seeking greater clarity,” Michaelstates.Thesameprinciplesthat rebuildapitcher’sendurancecanrestore vitalitytoanyone.
Forthefirstnineyears,ARRCLEDoperatedasaleanandfocused researchanddevelopmentcompany,dedicatedtorealizingitsmission ofturninga “Sick Person In, Healthy Person Out.” Michaelplayedan all-encompassingroleduringthistime. “Sonoe and I did everything for nine years, from developing the vision to manufacturing, managing, and even cleaning toilets,” hesayswiththegroundedhumilityofa founderwhohasexperiencedallaspectsofthebusiness.
Themostsignificantchallengeduringthisdecade-longinnovation cyclewasstrategic:fundingcutting-edgeresearchanddevelopment withoutanadvertisingbudget.Instead,thecompanyreliedsolelyonits reputationandreferralstosecurethenecessaryinvestments.
“
TheArchitectattheHelm
“For ten years now, ARRC LED and ARRC BIOTECH have built dozens of prototypes, and fortunately, thanks to our reputation, we kept the lights on,” Michaelexplains. “I am very grateful!”
Thisreflectsnotonlythepowerofthetechnology butalsothestrengthoftheirvision.Thecompany hasnotonlysurvivedbuthasthrived,buildinga globalreputationthroughthemostauthenticformof marketing:undeniableresults.
TheseresultsarethedrivingforcebehindARRC LED.Michaeltalksaboutwitnessingpatientsin terminalstagesofdiseaserecoverinjustweeks, militaryveteranswithcripplingPTSDfindingrelief, andathletesexceedingtheirpersonalbests. “Money is nice,” Michaelmuses, “but there is nothing like hearing a nine-year-old child talk about how the machine alleviates her pain so she can live a normal life.” Itisthesemomentsofprofoundhumanimpact thatvalidatetheimmenseinvestmentoftime, energy,andresources.
TheQuantumLeap
Withthecoretechnologynowperfected andvalidated,theteam’sfocushasshifted toanalmostunimaginablefrontier “This is where it gets FUN!” Michaelexclaims,his energypalpable.Thecurrentmissionisno longerconfinedtoaphysicaldevice;instead, itisaboutextendingitsreachthroughthequantum fielditself.
TheBlueprintofBeing
Tounderstandhowateamcanoperate comfortablyattheedgeofwhatseems possible,onemustlooktothefounder’s sourceofinspiration.Michael’slifereflects theblueprintheappliestotechnology,which consistsofatriad:Business,Performance, andEnergy.Hisbusinessacumenand knowledgeofbiochemistryprovidethe “what.” Hisdriveforathleticperformance showsthe “how.” Butitisthe “energy” componentthatanswersthe “why.”
“The biggest influences in my life have been the practices of Qi Gong, Buddhism, and Kriya Yoga Meditation,” Michaelshares.
“I have been incredibly blessed to witness the miracles these extraordinary masters can create. Experiencing it firsthand, repeatedly, changes you.”
Thisancientwisdomhelpstotranscendthe limitationsweoftenbelievewehave. “I absolutely know, at my core, that we can achieve more because I’ve seen it. The question is, can we replicate what the masters accomplish through their practice on a larger scale with technology?” Thisquestionshapes allofhisfuturisticendeavors.
Hispersonalmantradirectlyreflectsthis synthesis: “My spirit transcends my body. My body is here for a purpose, and for me, that mission is to explore the frontiers of wellness.”
Hisworkandlifearenotseparate;theyforma single,integratedmissiontoinvestigatethe upperlimitsofhumanpotential.
“I’ve created a quantum resonance portal that allows us to treat people remotely and document the outcomes,” Michaelreveals. “This is the future of medicine.” HereferstothisportalastheElysium Stargate,asystemthatconnectsanyone,anywhere intheworld,tothebioenergeticprogrammingofthe centralElysiumDevice. “We are building pods around the world to amplify the Stargate.”
Thegoalistotransformbothconsciousnessand healthonamassiveglobalscale,treatingthousands ofpeoplesimultaneouslywithoutphysicalcontact. Whilethisvisionsoundsstraightoutofscience fiction,Michaelandhisteamareactivelybringingit tolife.Inashowofsupremeconfidence,theyare evenofferingafree21-daytrial,invitinganyoneto experiencethefutureforthemselves.
Michael’sfinalmessageisnotoneof self-promotionbutoneofgratitudeand sharedpurpose,directedatthereaders themselves. “Thank you for being the people who are changing humanity! Those of you reading this are leading the charge... Thank you so much for being you.” Thisheartfelt acknowledgmentcomesfromafellow traveler—amanwhohasdelveddeeplyinto thescienceofourcellsandtheenergyofour spirit,returningwithabreathtakingvisionof whatwecanbecome.
Dr. Leen Kawas LeadingwithVisioninBiopharmaInnovation
Dr.LeenKawasknowswhatittakestodisruptan
industryandshehasdoneitwithbiotechinwaysfew couldimagine.Frompioneeringdrugdevelopmentsfor Alzheimer’stofoundingPropelBioPartners,alifescience investmentfirm,she’sbreakinggroundnotjustintreatments,but inhowtheentiresectorthinksaboutinvestment,growth,and inclusivity
Herstoryisnotoneofluckoreasysuccess.Everymilestoneis hard-won,groundedinrelentlessinnovationandaneyefor opportunitythatfewotherscansee.ForLeen,themissionhas alwaysbeenclear:developsolutionsthathavereal,lasting impactsonhumanhealth.Thismeansdiscoveringandinvestingin technologiesthatothersmightoverlookbutthatsheknowscan changelives.
TheRiseofaBiotechPioneer
Leen’sjourneyinbiotechdidn’tstartwithacushyroleor generousfunding.Shebuiltherexpertiseandcareerfromthe groundup.In2014,sheco-foundedAthiraPharmaandbroughtin groundbreakingideasaroundneurologicaldiseases.Inbiotech,the pressuretodeliverisn’tjustonprofitsbutonproducingtangible, life-savingresults.Leen’srelentlessdrivehelpedherraiseover $400million,culminatinginoneoftheindustry’smostnotable IPOs,andshediditwhilebreakingstereotypesleftandright.
What’sthesecret?Leenfocusesonthebigpicturewhilezeroing inoneverydetail.Shedoesn’tjustwantnewtherapiesinthe market—shewantstoreshapehowpatientsreceivethem,how researchersthinkaboutthem,andhowinvestorssupportthem.It’s avisionthatgoesbeyondproducts;it’saboutshapingthefutureof healthcare,andshe’sjustgettingstarted.
PropelBioPartners:RethinkingBiotechInvestments
NowatPropelBioPartners,LeenleadsasManagingGeneral Partner,targetingaveryspecificchallenge:findingthe biotechfirmswithpotentialfortransformationalchangeand givingthemthesupporttheyneedtogetthere.PropelBio Partnersisnotjustanotherinvestmentfirm;it’saplatformbuilt aroundcollaborationandsupportforhigh-potential,early-stage lifesciencescompanies.
“We’reinvestinginpeopleandideasthathavethe potentialtofundamentallyimprovelives,”shesays. Withafocusonbothsmall-cappublicandprivate companies,PropelBioistakingaholisticapproach. ForLeen,eachinvestmentdecisiongoesbeyond finance;itinvolvesevaluatingthetechnology,the team,andtheimpacttheycouldhaveonthefuture ofhealthcare.Hereyeforfindingandnurturing potentialdoesn’tjustcomefromyearsofexperience butfromadeep-rootedbeliefinwhatbiotechcan achievewhenfueledbytherightvisionandvalues.
ChallengesandTriumphsofBeingaFemale LeaderinBiotech
Inasectorwhereinnovationandprogressarekey, Leenhasseenthatforwomen,thepathisoften morechallenging.She’soneofjust22female foundersandCEOstotakeacompanypublicin biotechasof2021—astaggeringstatisticthat underscorestherarityofheraccomplishment. Despitetheseodds,Leendidn’tjustnavigatethe biotechlandscape;shereshapeditforherselfand thosewhocameafterher.
Butit’snotjustaboutbreakingrecords.Leenknows thatleadingacompanyinbiotechmeans confrontingauniquesetofchallenges.Whenshe ledAthirathroughitsIPO,itmarkedthefirsttimein over20yearsthatawomanhadguidedabiotech companytopublicstatusinWashingtonState.The recognition,whilesignificant,onlymadehermore awareoftheworklefttodoforwomeninscience andleadership.
“It’sharderasawoman;there’snodoubtaboutit,” shesays.“ButIdidn’tletthatdefinemeorlimitmy goals.”ForLeen,thefocusisclear:buildcompanies thatcanstandthetestoftime,andcreatepathways forotherwomentodothesame.It’sanapproach thathasseenhergainnotonlyindustryaccolades butalsothetrustandrespectofanewgenerationof femalescientistsandentrepreneurs.
BuildingaCompanyfromVision toIPO
TounderstandLeen’sleadership, looknofurtherthanherworkat Athira.Asco-founder,shedidn’tjust overseeoperations;shewasdeeply involvedinscientificresearchand drugdevelopment.Athira’slead candidate,ATH-1017,aimedat treatingAlzheimer’s,representsone ofhermajorcontributionstothe field.Bringingthistoliferequired notonlyscientificacumenbutalso thetenacitytosecurefundingand navigatethecomplexitiesofclinical trials,regulatorypathways,and publicinterest.
Raising$400millionand successfullytakingAthirapublic, Leenputherself—andthe company—onthemap.Shesays, “Thehardworkwasn’tjustin gettingtotheIPO;itwasinensuring thatwhatwewerebuildinghadreal substance,realpotentialtochange lives.”Thatclarityofpurposegave hertheedgeneededtoseethe companythroughitsmost challengingtimes,includingthe immensepressurethatcomeswitha publiclisting.
LeadingPropelBioPartners:A Hands-OnApproachtoInvesting
Today,atPropelBioPartners,Leen leverageseverythingshelearned fromheryearsatAthira.She’snot interestedinbeingapassive investor;she’sactivelyinvolvedin guidingportfoliocompanies, offeringstrategicinputoneverything fromregulatorypathwaystoproduct development.PropelBioisn’tjust aboutinjectingmoney—it’sabout beingpartofthejourney,ensuring thatthecompaniestheysupport havetheresourcesandguidancethey needtosucceed.
PropelBioPartnersoperatesona simplebutpowerfulpremise:real transformationinhealthcaretakes morethanjustcapital;ittakesa communityofexpertsand advisors.Byprovidingthis network,Leenandherteamare rethinkingwhatitmeanstobea lifesciencesinvestor.
“Everycompanyweworkwithis partofalargermissiontocreate better,moreeffectivehealthcare solutions,”shesays.ForLeen,it’s notenoughtoseeapromising technology;sheneedstoknowit hasthepotentialtobenefitpatients andthatit’sbeingledbypeople whosharethatcommitment.
AVoiceforWomeninBiotech
Beyondtheboardroomandlab, Leen’svoiceisoneofadvocacy. Sheactivelysupportsgender equity,butnotinaperformative way AtPropelBio,herfocuson diversityinportfoliocompanies happenednaturally,withamajority ofherfirm’sinvestmentslandingin women-ledventures.ForLeen,it wasn’taquotatobefilledbut ratherareflectionofherbeliefthat greatideascancomefromanyone andshouldbesupportedwherever theyarise.
“Sometimes,it’saboutjust showingupandprovingthat womencanleadatthehighest levels,”shesays.Leen’s straightforwardapproachresonates acrosstheindustry,inspiringother womentoseetheirownpotential inbiotechandentrepreneurship. Sherecognizesthatbeingoneof thefewwomentotakeabiotech companypublicismeaningful,but she’smorefocusedonensuring thatothersfollowherpath—and perhapsevensurpassit.
What’sNext?Revolutionizingthe InvestmentLandscapeinLifeSciences
AsLeenlookstothefuture,hergoalsfor PropelBioPartnersareambitious.She’snot contenttosimplygrowthefund;shewants tobuildaninvestmentmodelthatothersin theindustrycanlookto.Thismeansactively engagingwithcompaniesandsettinganew standardforwhatinvestorscan—and should—bringtothetablebeyondfunding. Hereyesareonthehorizon,thinkingabout theevolutionofpatient-centrichealthcare andhowPropelBiocanplayarolein makingitareality
Dr.Kawasisquicktopointoutthatherrole isfarfromconventional;sheseesherselfas partofanewbreedofinvestorswhoare deeplyinvolvedinthecompaniesthey support.“Weinvestmethodicallyand supportthoughtfully,”sheexplains.Forher, successisn’tjustmeasuredinreturnsbutin real-worldimpact,inseeingcompaniesshe backedachievebreakthroughsthatreshape thehealthcarelandscape.
LegacyandaVisionfortheFuture
Leen’sjourneyhasnotbeenaneasyone,and that’sexactlywhyit’ssoinspiring.From groundbreakingscientificworktobreaking downgenderbarriersinbiotech,herpathhas beenanythingbuttypical.She’ssettingan examplenotjustforfemaleleaders,butfor anyonewhobelievesinthepowerof innovationtomakeadifference.
Inanindustrythat’sslowtochange,Leen Kawasisacatalyst.HerworkatPropelBio Partnersisn’tjustaboutreturnsor prestige—it’saboutcreatingsomething biggerthanherself.She’savisionarywho’s rewritingtherulebookonwhatitmeansto lead,invest,andinnovateinbiotech.
ForDr.LeenKawas,themissionisclear: revolutionizehealthcare,onebreakthroughat atime.Andasshedoes,she’sshowingan entireindustrywhatitlooksliketoleadwith purposeandpassion.
Here’sahardtruth:Mostexecutivesdon’tquitbecause theycan’thandletheworkload.Theyquitbecausethey forgotwhytheworkmatteredinthefirstplace.
I’veseenitplayoutinbiotechlabs,pharmaboardrooms,andstartup incubatorsacrossthreecontinents.Brilliantscientists,razor-sharp strategists,productleadswhocannavigateregulatorymazesintheir sleep—allofthemontheedgeofburningitalldown.
Notbecausethey’reweak.Becausethey’vebeenlivinginreactive modefortoolong.Andtheproblemwithreactivemodeissimple: whenyou’reconstantlybelowdeckfixingtheengine,theshiphas noonesteeringit.Youcanbethehardest-workingcaptaininthe fleet,butifyounevergettopside,you’renavigatingblind.
TheWeekendThatProvedMyPoint
Twoweeksago,ItookpartinaleadershipretreatinNanpantan Hall—notthekindwhereyouendureeighthoursofPowerPoints underfluorescentlights.Thisonewasdifferent.Noartificial urgency, noback-to-backagendaitems,noempty“team-building”exercises.
Instead,therewasspace—actualbreathingspace—toaskthe questionsnooneinbiotechorpharmaseemstomaketimefor anymore:
· Whereisthiscompany really going?
· Doesthatdirectionstillmakesenseinthemarketwe’refacing?
· Whatexcitesmeenoughtopushthroughtheinevitable resistanceahead?
Theretreatincludeddeepstrategysessions, soundbaths,andevenTaiChiwitha practitionernicknamed“TheHealth Magician.”Weworked,butwealsolefttime tothink—which,ironically,isthethingmost leadersclaimtohavenotimefor
Andhere’sthekicker:thoseunstructured hoursproducedmorebreakthroughsthanany meticulouslyplannedoffsiteI’veattendedin thelastfiveyears.
RestIsNottheOppositeofWork
Inhigh-stakessectorslikebiotechandpharma, leaderstreatrestlikeasidedish.Something youmighthaveifyou'vefinishedyourplate.
Restisnottheoppositeofwork.
Thinkofitlikecellregenerationinthehuman body.Youcan’tgrowwithoutdowntime.Push yoursystemintoconstantstrain,andyou’re not“maximizingoutput”—you’redegrading yourinfrastructure.
Dino,oneofthefacilitators,summeditup betterthananywhitepaperevercould:
“Ifyou’realwaysbelowdeckfixingthe engine,noone’ssteeringtheship.”
That’snotjustacutemetaphor.It’stheoperationaltruthofanygrowing business.Inbiotech,thisisthedifferencebetweenbringingadrugto marketontimeandwatchingyourIPgetleapfroggedbyacompetitor whohadthedisciplinetostepback,recalibrate,andpivotearly
QuestionsWorthYourCalendarSpace
Let’sskipthegeneric“HowcanIbemoreproductive?”andgetinto questionsthatactuallysharpenleadershipthinking:
1.Whatwouldfeelexcitingtocreaterightnow?
Not“What'surgent?”Not“What’sontheroadmap?”Theprojectsthat createenergyforyoutendtocreateenergyfortheteam.
2.Whereisthiscompanyheading—anddoIstillwant toleaditthere?
It’seasytoinheritatrajectory.It’shardertoquestionitmid-journey.But ifyouneverdo,youriskbuildingsomethingyouwouldn’twanttorun.
3.Whatwouldmaketheworkitselfmoresatisfying?
Satisfactionisn’taluxurymetric.It’saretentionstrategy—foryouand yourbestpeople.
TheCEO’sClandestineAdvantage
Here’ssomethingthemosteffectivebiotechCEOsI’veworkedwithall haveincommon:theyknowwhentopullback. It’snotabout“workingless.”It'saboutstrategicdisengagement pullingoutoftheday-to-daychurnsotheycan:
· Identifymarketshiftsbeforethey’reobvious
· Reallocateresourcestowardemergingopportunities
· Maintainthementalclaritytomakecallsunderuncertainty
Thisisn’tmystical.It’smechanical.Justasamoleculeneedsstability beforeitcanformusefulbonds,acompanyneedsstabilityinits leadershiptoformusefulstrategies.
PlayIsaPerformanceTool
Duringtheretreat,wemadetimeforsomethingmostleaderswouldscoff at:play
No,notinthe“forcedfun”sense.Real,unstructuredplay.
WhatI’veseeninthelabandintheC-suiteisthesame:innovation doesn’tcomefromstaringharderatthedata.Itcomesfromgivingyour mindthespacetoconnectthingsitwasn’tconnectingbefore.
Playisn’tdowntime.It’sneural cross-training.
BurnoutPreventionIsaProfit Strategy
Here’swhatyouneedtoacceptif you’releadinginahigh-pressure, high-regulationindustry:avoiding burnoutisnota“soft”goal.It’sa profitstrategy
Burned-outleadersmakecautious, small-visionchoicesbecausetheir bandwidthisgone.Burned-out teamsshipsafe,forgettable productsbecausenoonehasthe energytochallengethebrief.
That’snotjustmorale loss—that’smarketloss.
TheRuthlessTakeaway
Beforeyoutorchtheblueprint, scraptheroadmap,orwalkaway fromaprojectyouoncebelieved in,trythis:
· Clearthedecksfor48hours.
· Stepawayfromyourroleasthe fixer.
· Askthequestionsthatmakeyou uncomfortable.
· Play,rest,reflect—withoutguilt.
Becausetheworkisn’tjustthe hoursyouputin.
Theworkisalsothespaceyou createfortherightideastoemerge.
You’renotbehind.You’re building.
Andthemostsustainable companiesinbiotechandpharma areledbypeoplewhounderstand thatrest,wonder,andplayareas muchapartofthejobasany quarterlyreview.
Chief Executive Officer | Exubrion Therapeutics
JENNIFER
The Quiet Strength behind a Quantum Leap in Animal Health KIRK
Onthesurface,JenniferKirk’scareerpath lookslikeaseriesofdisconnecteddots:a childhooddefinedbyaseriousmedical diagnosis,apragmaticpivotintothehigh-stakes worldofBigSixaccounting,atwo-decadeascent throughthefinanceranksofanoilgiant,andboard seatsatmassiveenergyandenvironmentalservices companies.It’saformidable,ifconventional, trajectory.Buttounderstandtherealstory,youhave tolookatthespacesinbetween,atthemomentsof quietreckoningandthedeeplypersonalmissions thathaveguidedher Youhavetounderstandthe storyofthe“throwaway”horses.
Today,JenniferKirkistheChiefExecutive OfficerofExubrionTherapeutics,aveterinary medtechcompanyonthecuspofrevolutionizing howwetreatosteoarthritisinourpets.Itisarole that,fiveyearsago,shecouldneverhaveimagined. Butitisalsotheroleshehasbeenpreparingforher entirelife.Herjourneyisatestamenttotheideathat ourtruecallingoftenfindsusnotthroughastraight line,butthroughaseriesofunexpecteddetours—a healthcrisis,afamilymove,achanceconversation onabusinesstrip.Itisthestoryofhowalifelong loveforanimalsandadeepsenseofpurposefinally convergedwithalifetimeofcorporatedisciplineto createsomethingtrulytransformative.
ForgedinGrit
ThestorybeginsinCalifornia,whereJennifer wasbornandraised.Atthetenderageofone, shewasdiagnosedwithType1Diabetes.The prognosisatthetimewasgrim;doctorstold hermothershewouldlikelybeblindorin kidneyfailurebytheageof20.Buther parents,fromalower-middle-class background,weredeterminedtodefythose odds.Theyinstilledinherafiercesenseof disciplineandresponsibilityaroundherhealth andeducation.Byagesix,inanactof extraordinarychildhoodgrit,shewasgiving herselfherowninsulinshots.
Thisearlycrucibleforgedtheprecisionand resiliencethatwouldbecomethebedrockof hercareer.Herchildhooddreamwastomajor inlinguisticsandrunadogrescue,butthe practicalrealitiesofherconditionmadesolid healthinsuranceanon-negotiable.Shemadea pragmaticpivot,choosingEconomicswitha focusinaccounting.Thedecisionnotonly gaveherthestabilitysheneededbutalsoset heronapaththatwouldlead,decadeslater,to thehighestechelonsofcorporatefinance. Becomingthefirstpersoninherfamilyto graduatefromcollegewasnotjustamilestone; itwasthefoundationofeverythingtocome.
TheCorporateAscent
AfterastintataBigSixaccountingfirm, Jenniferspent22yearsatOccidental Petroleum(NYSE:OXY),risingthrougha seriesofdemandingfinancerolesthatincluded VPofFinance,ChiefAccountingOfficer,and ultimately,SeniorVicePresidentleadingthe integrationofa$57billionacquisition.The fast-paced,globalenergysectorwasapowerful trainingground,givingheropportunitiestolive inmultiplelocationsandtravelextensively
Duringthistime,shebroadenedher perspectivebyjoiningtheboardsofmajor publiccompanies.In2016,shewasappointed totheboardofRepublicServices(NYSE: RSG),aleaderinenvironmentalservices.In 2024,shejoinedtheboardofSempra(NYSE: SRE),aFortune500energycompany
Herreputationwascemented:arecognized financialexpertwithadeepunderstandingof riskmanagement,M&Astrategy,andcorporate governance.Shewasatitanoffinance,amaster ofaworldofnumbersandshareholdervalue. Butadifferentcallingwasbeginningtostir
Hearts,Horses,andaNewDirection
In2021,amidsttheglobaldisruptionofthe pandemic,Jenniferfeltadeeppulltowardwork thatalignedmorepersonallywithhervalues. Thisledhertoaseniorfinanceroleat Medtronic,theglobalmedtechleaderthat,ina poeticconvergenceofherpersonaland professionallives,manufacturedthevery insulinpumpsheusedeveryday.Sherelocated herfamilyfromTexastoMinnesota,embracing anewchapter
Itwastherethatherlifelongloveforanimals foundaprofoundnewexpression.Seekinga groundingactivityfortheirthreedaughters, Jenniferandherhusband,Adam,tookthemtoa localhorseranch.Theymetawomannamed Bree,aguidinglightwhoshowedthemthe therapeuticpowerofhorses—especiallythe overlookedanddiscardedones.Jennifer witnessedfirsthandthecalmingeffectthese “throwaway”horseshadonhermiddle daughter,andeverythingshifted.“Oncewesaw it,”sherecalls,“weknewwehadtodo something—notjusttorescuethehorses,butto givethempurposeagainbyhelpingpeople heal.”ThiswasthesparkthatignitedHealing withHorseplay,arescuemissionthatbecamea deeplypersonalcallingforherentirefamily
TheCalltoLead
Thefinal,unexpecteddotwasconnectedona Medtronicbusinesstrip.Jennifermetawoman namedLaurie,whowouldonceagainchange thecourseofhercareer Theyconnected instantly,andwhenJennifersharedthestory ofthehorserescue,itsparkedadeeper conversation—firstaboutjointhealthin animals,thenaboutanovelisotopecalled Tin-117m,andultimatelyabout ExubrionTherapeutics,acompanyLaurie hadinvestedin.
Oneconversationledtoanother. Laurieeventuallydecidedtoleadthe nextroundoffundingforExubrion, butwithacriticalcondition:Jennifer hadtoagreetoleadthecompany LauriesawinJenniferarare combinationofstrategicclarity, financialacumen,andadeep,personal passionforanimalsandmedtech.The boardandfoundingteamagreed.In Mayof2025,thefinancetitanwhohad startedoutdreamingofananimal rescueofficiallybecametheCEOofa veterinarymedtechcompany
Today,sheleadsasmallbutmighty teamunitedbyasingle,resonant mission:improvingthelivesofpets livingwithosteoarthritis.Every memberoftheteamisapetparent, bringingapersonalpassiontotheir work.Sheissurroundedbyauniquely qualifiedteam,includingEric,the CCOwith30yearsofexperience; Nigel,theCOOandoneofthe technology’soriginalinventors;Bob, theempatheticChiefVeterinary Officer;andTim,theseasoned productionmanager Atthetop,Laurie servesnotjustasboardchair,butasa trustedcoachandthoughtpartner.“It’s aloteasiertoleadwhenyoubelieveso deeplyintheproduct,”Jennifersays.
ALegacyinLayers
AtExubrion,Jenniferissteeringa revolutioninanimalhealth.The company’spioneeringtreatment, ™ SynovetinOA ,isnotapainkiller;itis atargetedradiotherapeuticthat addressestheunderlyinginflammation thatcausesarthritis.Withatotal addressablemarketofover$6billion annuallyforthe20milliondogs sufferingfromosteoarthritisinthe U.S.alone,thegrowthpotentialis enormous.Hergoalistomorethan doublesalesyear-over-yearforthe nextthreeyearsandexpandintothe equinemarket.
ButforJennifer,thelegacysheisbuildingisaboutmorethan marketshare.Itisaboutintegratingherlife’spassionsintoa single,cohesivepurpose.“Iwanttosetanexamplethatit’s possibletoloveyourworkandincorporateitnaturallyintoyour life,”shesays.Heradvicetoaspiringwomenleadersinbiotech isareflectionofherownjourney:“Leadwithbothheadand heart.Inbiotech,wedealwithdataandmolecules,but ultimatelywe’reworkingtoimprovelives.That’snotasoft skill—it’sastrategicasset.”
Ultimately,hergoalistobuildalegacyofcompassion, innovation,andintegration,provingthatitispossibletocreate meaningfulchangeatwork,athome,andinthecommunity
Thelittlegirlwholearnedresiliencefromachronicillness,the financeexecutivewhomasteredtheartofthedeal,andthe motherwhofoundpurposeinarescuedhorsehaveall convergedintooneremarkableleader,nowpoisedtobring healingtomillionsofourbestfriends.
Inpharmaandbiotech,weoftenrunthesameriskas early-stageentrepreneurs:wefallinlovewithanidea beforewetestwhetherthemarketlovesitback.
Thismistakehappensateverylevel.Fromstart-upfounders pushinga“game-changing”therapywithoutenoughclinical traction,tomultinationalexecutivesgreenlightingaproduct linebasedoninternalexcitementratherthanexternaldemand.
I’vemadethesamemistakemyself.AndwhenIdid,Ilearned oneofthemostprofitablelessonsofmycareer:
Beingtooweddedtoaspecificoutcomeblindsyoutothe betterpathrightinfrontofyou.
When“GreatonPaper”MeetsReality
Afewyearsago,IhadwhatIthoughtwasaperfectplan.
professionalofferIbelievedwasirresistible.
Ihadaresourcesittingidle.Ihadanetworkthatcouldbenefit fromit.Ihadthemotivationtomakeithappen.
IputtheideainfrontofsevenpeopleIconsideredanidealfit. Thekindofpeoplewhoregularlyexpressedinterestinexactly thistypeofopportunity.
Iexpectedatleastacoupleofquick“yes”replies.Bags packed.Commitmentsmade.
· “That’sanamazingoffer.”
· “Wow,I’dloveto…butnotrightnow.”
· “I’llthinkaboutit.”
Andthen—silence.
Nosign-ups.Noaction.Noconversion.
TheBlindSpot
Icoachleadersallthetimeonthefundamentalsofa compellingoffer:
· Understandtheproblemyousolve—inprecise, market-relevantterms.
· Showexactlywhyyoursolutionworks,withevidence andproof.
· Connecttotheurgencythatalreadyexistsinyour audience’smind.
· Maketheoffersoalignedandsoclearthatrejection feelsirrational.
· Putitinfrontofenoughofthe right people—notjust peoplewhomight“like”theconcept.
Ididnoneofthesethings.
ImadeanofferbasedonwhatIwantedforthem—noton whattheywereactivelyseeking.
Iremovedallfrictionbutalsoremovedallcommitment.
Andwithouturgency,cost,ordirectalignmentwiththeir priorities,theydidwhathumansusuallydowithrisk-free, low-commitmentoffers:
ThePharmaParallel
Ifyou’vebeeninbiotechorpharmaformorethana quarter,you’veseenthispattern.Companieslaunch “can’t-miss”productsorserviceswithhighinternal enthusiasm…onlytowatchthemstall.
Why?
Becausetheinternallogic(“Thisisbrilliant!Itwillhelp themsomuch!”)doesn’talwaysmatchthemarketreality (“We’renotready,we’renotconvinced,wehavebigger firestoputout.”).
It’sthesamereasonpromisingmoleculesget shelved.Notbecausetheylackpotential,but becausetheyfailtosolvethe urgent, budgeted problem thatdecision-makersneed solved right now
DetachingfromtheOriginalOutcome
Initially,Iwasirritated.Notbecauseanyone owedmea“yes,”butbecausemyconfidence intheideahadbeensohigh.
Butwhentheoutcomedidn’tmatchthe expectation,Ifacedachoice:
1.Keeppushingthesameoffertothesame peopleandhopepersistencewouldwork.
2.Stepback,re-examine,andpivot.
Ichosethesecond.
Here’sthethinkingprocess:
· Wastheaudienceright?Technically yes—theyfittheprofile.Buttheyweren’t inanactivebuyingstateforthisoffer.
· Wastheofferclear?Notinthewaythat sparksimmediatecommitment.
· Wasthereskininthegame?No.Andthat wasthebiggestgap.
TheRebuild
Insteadofofferingtheresourceforfree, Ireframeditasapremium,focused engagement.Aspecificoutcome.Adefined timeframe.Apricetagthatsignaledvalueand requiredcommitment.
Ididn’tjustinvitepeopleto“come experience”something.
partnershipwithme—inanenvironmentthat removeddistractionsandaccelerated progress.
Thepositioningchangedeverything.
Withinweeks,peoplewhohadpolitely passedonthefreeofferwerepayingforthe structuredone.
WhyThisWorks(AndAlwaysHasinOurIndustry)
Inbiotechandpharma,“free”rarelydrivesactionatthe executiveorstrategiclevel.
requiresinvestment.
Whencompaniesandindividualspay,theyfocus.Theyallocate resources.Theypreparetocapturethevalue.
Therepackagedofferworkedbecauseit:
· specificproblem Defineda (businessownersstuckin operationalgrind).
· clearsolution Offereda (twodaysofstructuredstrategywith measurableoutcomes).
· Requiredemotionalandfinancialcommitment(theactof payingmadethemprioritize).
· Targetedtherightaudienceattherightstage(leaders activelyseekingbreakthrough,notpassiveobservers).
TheExecutiveTakeaway
Whetheryou’repushingapersonalofferorlaunchinga multimillion-dollartherapy,theprincipleisidentical:
Ifthemarketdoesn’tengage,don’tdoubledownonthe originalformoftheidea.
Instead:
1.Audittheaudiencefit.Didyoutargetpeoplewiththe immediateproblemyousolve?
2.Examinetheofferclarity.Couldtheyinstantlyconnectyour solutiontotheirpainpoint?
3.Checkthestakes.Wasthereenoughcost,risk,orurgencyto forceadecision?
Ifanyoneoftheseisweak,yourconversionswillbetoo.
WhyBeing“WeddedtotheOutcome”IsRiskyforLeaders
Whenyouemotionallycommittoaspecificversionofsuccess, youstartignoringdatathatcontradictsit. partnerships,andevenhiring.
Youinterpretlukewarminterestas“theyneedmoreconvincing” insteadof“thisisn’ttherightfitrightnow.”
becauseyou believe theywilleventually
ThePivotMindset
Detachmentdoesn’tmeanapathy.It meansrefusingtoletonepossible outcomebetheonlyoneyoupursue.
Inpractice,itlookslikethis:
· Yourunthepilotcampaign.The uptakeislow
· Insteadofdefendingthepilot,you runastructuredpost-mortem.
· Youidentifymisalignmentpoints.
· Yourepackage,reframe,or reposition—andtestagain quickly.
Inbiotechterms:yourun thetrial,youanalyzethe endpoints,andiftheefficacydata isweak,youadjustthe formulationorindicationratherthan pushingthesamedoseina biggertrial.
APersonalRuleIApplytoEveryLaunch
WheneverItakesomethingtomarket—beitaservice,astrategy session,oramajorresearchcollaboration—Irunitthroughthisfilter:
Ifnoonesaysyes,isthisideastillworthpursuinginadifferent form?
Iftheanswerisno,IknowI’mtooattachedtothecurrentformand notfocusedenoughontheunderlyingvalue.
FinalLessonsYouCanApplyNow
· Don’tconfuseinterestwithintent.Peoplecanloveyouridea withoutbuyingit.
· Addstakes.Timelimits,cost,orcompetitiveadvantagemake decisionshappen.
· Scaleyoursamplesize.Sevenconversationswon'tgiveyoumarket truth.
· Detachfromform,protectthecorevalue.Thebestoutcomes oftenappearinthesecondorthirditeration.
Intheend,thepivotdidn’tjust“save”myidea—itmadeitstronger, moretargeted,andmorevaluabletothepeoplewhoneededitmost.
Andinbiotechandpharma,that’sthegamewe’reallplaying:turning promisingconceptsintomarket-readysolutionsbylettingthedata,not ourego,guidetheway
Chief Executive Officer I Diadem SpA
MICHAEL RASCHE
Charting a New Course against Alzheimer
MichaelRaschegraspstheenormous weightofhistask.AsChiefExecutive OfficerofDiademSpA,heleadsa companythatdirectlyconfrontsoneofmedicine’smost profoundchallenges:Alzheimer’sdisease.Hiswork focusesonwhathas,untilnow,remainedlargelyoutof reach—early,accuratediagnosis.Raschebringsacareer builtonnavigatingcomplexsystemsanddriving growthwithinthelifesciences.Now,heappliesthat experiencetoabloodtest,asimpletoolthatpromises toupendhowweunderstandandmanageadevastating illness.
ForgingaPathinLifeSciences
Rasche’sjourneyintohealthcarebegan,henotes,close toLeverkusen,Germany,thehomeofBayerAG.This proximityshapedhisearlythinking.Helearned healthcaremovedbeyondproducts;itfundamentally changedlives.Thisinitialunderstanding,combined withaburgeoningglobalperspective,ledhimto businessadministrationstudiesatBayerUniversity.He sawhealthcareasaplacewherebusinessacumencould mergewithsignificantsocietalimpact.
HisearlyyearsatBayer,thenatRoche,laidhis foundation.Helearnedglobaloperations,theprecision indiagnostics,andtheartofassemblingeffective teams.Overthenexttwodecades,rolesatDako,Leti Pharma,andMetabolonfollowed.Eachpositionadded layersofresponsibility,refininghisapproachto leadership.Theseexperiences,heexplains,sharpened hisabilitytoguidediverseteamsandimplement innovativestrategies.Hiscareer,hestates,moved acrosscontinents,eachrolebringingnewchallenges andinsights.HeconsidershisarrivalatDiademSpA theculminationofthisjourney
Diadem’sUrgentMission:EarlyDetection
AtDiadem,Rascheconfrontsamissionofimmense urgency.Thecompanydevelopsandcommercializes ®AlzoSure Predict.Thisblood-basedassaypredicts whethersymptom-freeindividuals,aged50orolder, willprogresstoAlzheimer’sdiseasewithinatwo-or six-yeartimeframe.Theteststandsoutforitsnoninvasiveness.Itdetectsthedisease’spresencebefore symptomsmanifest,offeringacrucialwindow.This earlyinsightprovidespatientsandtheirfamiliestimeto plan.Itallowshealthcareprofessionalstoconsider interventionswhentheymightmakearealdifference.
Raschedefinesthecompany’sobjectivewith clarity:“AtDiadem,ourgoalistoadvance diagnosticsandredefinetheirroleinpatientcare, empoweringproviderswithinsightsthatdrive betteroutcomes.”Heguidesthecompanythrough intricateregulatorypathways,withFDAapproval ® fortheU.S.marketaprimaryobjective.AlzoSure Predictoffersamoreaccessibleandaffordable alternativetoexistingmethodslikePETscansand lumbarpunctures,whichcarryhighercostsand involveinvasiveprocedures.Bymakingearly diagnosismorewidespread,Diademseekstoease theburdenonhealthcaresystemsandonpatients themselves.
Rascheenvisionsafuturewhereearlydetection andinterventionfundamentallychange Alzheimer’scare.Thisshift,hebelieves,willslow diseaseprogression,refinetreatmentapproaches, easetheburdenoncaregivers,accelerateclinical trials,andenergizetheglobaleffortagainst Alzheimer’s.
TheDisciplineofBalancedLeadership
Rasche’sleadershipphilosophyrestsonaconcept hecalls“balance.”Hestates,“Balancesets boundariesandinspiresotherstodothesame.” Thisapproach,hemaintains,cultivatesan environmentwhereinnovationandwell-being thrive,ensuringsustainablegrowth.Hispersonal disciplineinvolvesadeliberateseparationofwork andfamilytime,especiallyonweekends.Hefinds groundingandenergyinlong-distancerunsand otherpersonalpursuits.Bydelegatingtasks, prioritizingresponsibilities,andstreamlining communication,hebuildsateamculturethat valuesbothprofessionaloutputandpersonal fulfillment.
Asignificantachievementinhiscareer,herecalls, occurredduringhistimeatRocheDiagnostics.His teamearnedtheFrost&SullivanAwardfor“Best MarketingOrganization”intheIVDindustry This award,henotes,recognizedastrategicpivot.They movedfromaproduct-focusedapproachtoone thatprioritizedstreamliningworkflowsand deliveringclearvaluetohealthcareproviders.This newstrategy,coupledwithadeepunderstandingof providerneeds,provedtransformative.Itremains, forRasche,ahighlightofhiscareer
Rascheplacesahighpremiumonteambuilding.Heviews himselfasamentorwhofostersenvironmentswheretalent flourishesandcollaborationstrengthens.Thetrustand respecthehasbuiltwithteammembersacrossvarious companiesandroles,hestates,representoneofthemost fulfillingaspectsofhisprofessionaljourney
ConfrontingtheChileanLabyrinth
Hiscareerincludesnavigatingsignificantchallenges.One suchinstanceinvolvedrestructuringRocheDiagnostics’ LatinAmericanoperations,particularlyinthecomplex Chileanmarket.Hedecentralizedoperationsintothree regions,eachwithitsownprofitandlossresponsibility Thisrestructuring,heacknowledges,presentedacomplex task.Itmetinitialresistance.Raschepersisted.Through clearcommunicationandfocusedteamengagement,he unitedhisteam,builtconsensus,andguidedthechange process.Theoutcome,hehighlights,wasasignificant increaseinbothsalesandprofits,demonstratingthepower ofsystematicrestructuringtodrivegrowth.
StrategicImperativesandaFutureBlueprint
Rascheemploysspecificstrategiestomaintainprogress.He buildspartnerships,liketheonewithQuestDiagnostics,to expandreachandimpact.Healsosecurescrucialfunding throughSeriesBinitiatives,fuelingDiadem’sambitious journey Theseefforts,hebelieves,providetheresources necessarytoscaleoperations,advanceresearch,andenter newmarkets,solidifyingDiademSpA’spositionasaleader indiagnosticinnovation.
Heapproachesstrategicplanninglikeanengineerdesignsa bridge,combiningflexibilitywithafocusonoutcomes.He emphasizesdata-drivendecision-makingandpromotes organizationalaccountability.Hemonitorsmetricsclosely, ensuringstrategiesalignwithgoals.Thiscombinationof responsivenessandprecision,heasserts,consistently deliversimpactfulresults.
Rascheseesthefutureofhealthcaremovingtoward personalizedsolutions.“Thefutureofhealthcareliesin patient-centeredsolutions.DiademSpAcommitstoleading thistransformationwithinnovativediagnostics,”hestates.
® Diadem’sAlzoSure Predict,targetingtheU-p53AZ biomarker,will,hebelieves,leadthewayinearly Alzheimer’sdetection.Bybridgingthegapbetween technologyandpatientneeds,Diademaimstoprovide accessible,personalizeddiagnostics,includingfor underservedregions,changingthehealthcarelandscape.
Asafather,Raschefeelsastrongdesiretoprotect ® futuregenerations.BymakingAlzoSure Predict accessible,Diademempowershealthcareprovidersto detectAlzheimer’searly,wheninterventionscan makeatruedifference.Thismission,hestates,aligns withhisconvictionthatearlydiagnostics significantlyenhancepatientoutcomesandpavethe wayforahealthierfutureforgenerationstocome.
CultivatingtheNextWaveofLeaders
Withovertwodecadesofexperiencegrowing businessesinlifesciencesandhealthcare,Rasche nowdedicatessignificantefforttoguidingthenext generationofhealthcareleaders.Headvisesthemto prioritizecontinuouslearning,empathy,and resilience.Healthcare,hestresses,isafast-paced field.Leadersmustremainlifelonglearners,curious andopentonewideas.Empathy,hecontends,is key—understandingtheneedsofpatients,doctors, andstaffdrivesrealchange.Setbacksareinevitable, heobserves,buteffectiveleadersseethemas opportunitiestolearnandgrow.Inhiswords:“True leadershipinhealthcareembraceschallenges,learns continuously,andinspiresotherstomakea meaningfuldifference.”Hebelievesinthepowerof people.Heurgesaspiringleaderstoinvestinpeople andfosterasupportiveculturetodriveimpactinthis complexfield.
DrivingInnovationthroughAction
Rasche’sleadershipphilosophyhingeson empoweringteams,fosteringaccountability,and drivinginnovationforsustainablesuccess.Hesets clear,strategicgoalsandemphasizesdisciplined execution,consistentlyinspiringhisteamstoperform attheirbest.Hehasbuiltareputationforaligning visionwithactionanddeliveringmeasurableresults. Hisapproachencouragescollaborationandinstillsa senseofownershipwithinhisteams,allowingthem tothriveindynamicenvironmentsandexceed expectations.
Toremaincurrent,Rascheactivelyseeks opportunitiestoexpandhisknowledge.Heattends conferences,engageswithexperts,andexplores interdisciplinaryfieldslikebiotechnologyand artificialintelligence.Thisdedicationkeepshimat theforefrontofindustrytrendsandallowshimto spearheadadvancementsindiagnostics.
Hedescribeshimselfasa“doer”andholdsabold, ambitiousagendaforDiademSpA.Heaimstomake accurateandeffectivediagnosticsaccessibletoall.With afocusoninnovationandglobalexpansion,Diadem intendstobringgroundbreakingsolutions,like ®AlzoSure Predict,topatientsworldwide,regardlessof location.Heshares:“MyvisionpositionsDiademasa leaderinglobalhealthcare,transformingdiagnostics withinnovationsthattrulymeettheneedsofpatients andproviders.”
DiademSpAlookstothefuture,holdingfirmtoits missiontotransformhealthcarethroughaccessible, cutting-edgediagnostics.GuidedbyRasche’sclear direction,DiadempreparestoredefineAlzheimer’scare onaglobalscale.Thecompanyfocusesoninnovation anddeliversimpactfulsolutions.Itbreaksnewgroundin earlydetectionandintervention,empoweringclinicians, patients,andfamilies.UnderRasche’sleadership,the companywillshapeafuturewhereadvanceddiagnostics drivebetteroutcomesandrevolutionizetheapproachto Alzheimer’sdiseaseworldwide.
THEPARADOXOFPROGRESS Why More Money (Alone) Won’t Fix WOMEN’S HEALTH
Weseetheheadlines.Recordfunding.Venture capital,finally,wakinguptotheenormous, underservedmarketthatiswomen’shealth. Lastyear,2024,sawapeak:$2.6billionflowingin.That’s upfrom$1.7billionin2023.Greenshoots,indeed.
Themoneyisn’tjustchasingappsanymore.Asolidthird ofit,we’retold,isnowtargetingbiopharma.Realscience. Treatmentsformisunderstood,oftendebilitatingconditions likeendometriosis,polycysticovariansyndrome.A genuineefforttotacklepreeclampsia,athreattomothers andbabiesthatwe’vetoleratedfortoolong(hattipto companieslikeComancheBio,pullingin$75million).
There’sevenadawningrecognitionthat“women’shealth” isn’tjustaboutreproduction.It’sabouthowautoimmune diseases,heartconditions,bonedisease–majorrevenue driversforpharma–uniquelyimpacthalfthepopulation. Thescope,asanSVBanalystrightlypointedout,is growing.Andabiggerscope,logically,shouldpainta brighterpicture.
But.
Andit’sasignificant“but.”
Moneyflowswhereitseesapath.Innovation,especially thefoundationalkind,thekindthatleadstobreakthrough drugs,oftensproutsinthesoilofacademia,nurturedby publicinvestment.
Andthat’swheretheparadoxkicksin.
ThepreviousBidenadministrationlaunchedthe WhiteHouseInitiativeinWomen’sHealthResearch Anecessarystep.$113milliondistributed.Butitwas lateinthegame.AsProfessorSabraKleinfrom JohnsHopkinsstarklyputit,“Bythetimeitgotgoing, theylosttheelection—andit’sover.”Ayearisn’t dedication.It’sanod.
Now,considerthecurrentlandscapeunderPresidentTrump. Thesignalsare,shallwesay,mixed.Concerning,even.We’re hearingaboutslashedgrantfunding.MajorNIHstudies,like thedecades-longWomen’sHealthInitiative–abedrockof dataonmenopause,osteoporosis–sawitsfederalfunding threatened,thenputinlimbo.Whenyou’realreadydedicating apaltry8.8%ofNIHresearchfundingtothehealthof51%of thepopulation(astatisticfromtheNationalAcademiesthat shouldmakeusallpause),canyouafford any slowdown?
DaréBiosciences’CEO,SabrinaJohnson,doesn’tmince words:“Thefieldofwomen’shealthisalreadyunderserved,so wecan’treallyaffordfurtherslowdown.”
Thenthere’sthechillingeffectofpolicy TherollbackofDEI initiatives,theinsistenceonacknowledgingonlytwo sexes–thesearen’tjustsemantics.Theycreatebureaucratic hurdles,theydiscourageresearchthatdoesn’tfitanarrow mold,andtheycertainlydon’thelpafieldthat,until1993, wasn’tevenrequiredtoincludewomeninNIH-fundedclinical trials.Wehavedecadesofinformationdeficittoovercome.
Anditripples.CutsatHealthandHumanServices,evenif positionedasnotaffectingfrontlinereviewersattheFDA, createuncertainty.Foranindustrylikewomen’shealth,with relativelyfewproductshistoricallynavigatingtheFDA,any disruption,anyperceptionofslowdown,ismagnified.
So,what’stherealstoryhere?
Isittheoptimisticglowofventurecapitalfinallyseeingthe light?Orisittheflickering,uncertainflameoffoundational research,buffetedbypoliticalwinds?
Thetruthis,it’sboth.Andthat’stheproblem.
Privatecapitalisessential.Itfuelsgrowth,itbrings productstomarket.Butitrarelyfundstheriskiest,earliest science.Thekindofsciencethat’s“underfunded”and “under-acknowledged,”asexpertslikeMarcelleCedars fromUCSFhighlight.
Ifthepipelineofacademicresearch–the wellspringoffutureinnovation–isdecimated overfouryears,itwon’ttakefouryearsto rebuild.Itwilltakedecades Werisklosingnot justresearchers,butourstandingasleadersin biomedicalinnovation.
Thisisn’tjustabout“women’shealth.”It’sabout ourapproachtohealth,period.It’saboutwhether we’rewillingtomakesustained,long-term investmentsinthewell-beingof everyone
Theprivatesectorseesanopportunity.That’sgood.Butthis momentmightalsobeastarkcall:acallforprivatecapitalto considersteppingfurtherupstream.Toinvestintheriskier, foundationalsciencethatthepublicsectorseemsincreasingly hesitant,orunable,toconsistentlychampion.
Becausewithoutthatfoundationalscience,therecordventure capitalchecksoftodaymightjustbefundingyesterday’s ideastomorrow.
Andthat’saparadoxwecan’tafford.
Cho Miriam
How a Mother of Three Reinvented a Pharmacy Empire
MiriamCho’schildrenarehergreatestmotivation.It’sasimple,deeplyhuman factthatunderpinsacareerofremarkablecomplexityandsuccess.Asthe PresidentandChiefPharmacyOfficerofMACRx,sheoverseesamulti-state long-termcarepharmacyoperationservingover30,000individualsintheMidwest.She navigatesthelabyrinthineworldsofMedicarePartD,theInflationReductionAct,andthe opaquepracticesofPharmacyBenefitManagers.Buttounderstandhowshegothere,you havetolookpasttheC-suitetitlesandtheimpressivegrowthcharts.Youhavetogoback21 years,toayoungpharmacystudentonatraditionalpath,andasinglephonecallthatwould changeeverything.
Herstoryisnotoneofameticulouslyplannedascent.Itisastoryofahappyaccident,ofa womanwho,inseekingabetterwork-lifebalanceforherfamily,stumbledintoanindustry sheknewlittleaboutandproceededtorevolutionizeitfromtheinsideout.Asthedaughterof first-generationimmigrants,sheisdrivenbyadesiretoprovideherchildrenwith opportunitiessheneverhad.Thisquiet,powerfulmotivationhasfueledhertransformationof afledglingpharmacyintoathrivingenterprise,builtnotoncutthroattactics,butonaradical commitmenttoservice,personalconnection,andthebeliefthatinthehigh-stakesworldof healthcare,themostvaluablecurrencyistrust.
TheUnplannedDetour
Twenty-oneyearsago,MiriamChowasdoingwhatwasexpected.Shewasfinishingher DoctorofPharmacyatMidwesternUniversityinIllinoisandembarkingonacareerin corporateretailpharmacy.Itwasawell-troddenpath,stableandsecure.Butitdidn’ttakelong forhertorealizethatitdidn’talignwithhergoals.Thecorporateworldfeltimpersonal,the trajectoryunfulfilling.
Theturncameunexpectedly.Aformercolleaguereachedoutaboutanopportunityatanewlyestablishedpharmacycalled MACRx.Miriamknewnexttonothingaboutlong-termcare,butthepromiseofabetterwork-lifebalanceforamotherof threewasapowerfullure.Sheexploredtheopportunityandwashired.Uponarriving,hersharpeyeforoperations immediatelyidentifiedareasforimprovement.Afewmonthslater,inDecember2015,shewasofferedthepositionof PharmacistinChargeandDirectorofPharmacy.Sheaccepted.Thefollowingyear,shewaspromotedtoChiefPharmacy Officer
Whathappenednextwasnothingshortofexplosive.Underherleadership,thepharmacybegantoexperiencestaggering growth,achievinga48%year-on-yearincreasesince2016.In2021,MACRxexpanded,acquiringasecondlocationin Indiana.ThiswasfollowedbythelaunchofanewstartupinMissouriinJune2023.Thewomanwhohadenteredthe industrybychancewasnowleadingitschargeacrosstheMidwest.
TheGospelofService
AskMiriamChotonamehercompany’spriorities,andshewilltellyouitisaservice-firstapproach,withcostsavingsasa closesecond.“Exceptionalserviceisthemostimportant,”shesays,withouthesitation.Inthecomplex,oftenimpersonal worldoflong-termcare,MACRxhasbuiltitssuccessonafoundationofhumanconnection.Miriambelievesinbeinga “truepartner”toherclients,whichmeansbeingpresentonthefrontlines,notjustintheboardroom.
Thisphilosophymanifestsinwaysthatarealmostunheardofinalargeindustry.ManyofMACRx’spartnershaveMiriam’s personalcellphonenumber,alongwiththecontactinformationforothermembersofherleadershipteam.Thislevelof accessibilityfostersadeepsenseoftrustandpartnership.Itisastrategyofradicaltransparencyandpersonaltouchinasector thatcanoftenfeelbureaucraticanddistant.Thiscommitmenttobuildingpersonalizedrelationshipsisnotjustastrategy;itis thecoreofherbusiness,andshecreditsitwiththecompany’simpressiveclientretentionrates.
NavigatingtheMaze
Thehealthcareandpharmaceuticallandscapeisa constantlyshiftingmazeoflegislationandregulation. Oneofthemostsignificantcurrentchallengesisthe implementationoftheInflationReductionAct(IRA), whichisintroducingsweepingchangesto reimbursementstructures.
Whilemanyintheindustryviewthesechangeswith apprehension,MACRxhastakenaproactivestance. Miriam’sapproachisnottowaitandsee,butto advocate,engagewithpolicymakers,andeducatethem onthevitalrolethatlong-termcarepharmaciesplayin servingvulnerablepopulations.
Atthestatelevel,thechallengesarecompoundedby reimbursementlegislationthatoftenputsfinancial authorityinthehandsofPharmacyBenefitManagers (PBMs),entitiesthat,asMiriampointsout,exert significantnegativecontroloverthefinanciallandscape. Navigatingthesecomplexitiesrequiresadeep understandingoftheindustryandawillingnessto challengetheopaquepracticesofPBMs.Itisafightfor transparency,notjustforherownpharmacies,butfor thehealthofthebroadersystem.
TheGreenhouseforGrowth
MiriamCho’sleadershipstyleisthatofacultivator.She isdeeplyinvestedinthegrowthofherteam,apassion thatisonfulldisplayatthecompany’squarterlyoff-site leadershipconferences.“Ifindmotivationinhelping individualsthriveandsucceedwithintheorganization,” shesays.Thisfocusoninternaldevelopmentismatched byarelentlessdriveforinnovation.
MACRxwasoneofthefirstpharmaciestohirenurses aspartofitscustomerserviceteam,amovethat integratedessentialclinicalskillsdirectlyintothe servicemodel.Thecompanyhasalsostartedoffering accreditedwebinarstoitsnursingfacilitypartners, furthercementingitsroleasaneducationalpartner Now,sheispushingthecompanyintothefuture,witha strongemphasisonautomationandAIinnovation.“Iam eagertoseetheresultsandcustomerresponsesaswe begintorollouttheseadvancementsinQ3andQ4of thisyear,”shesayswithpalpableexcitement.Hervision isclear:toleveragetechnologytoimproveclinical outcomes,enhanceefficiency,andminimizethe potentialforhumanerror
TheUnspokenSuperpower
Inafieldwhereleadershippanelsandboards oftenlackfemalerepresentation,Miriamhas carvedherownpath.“Asaminorityfemalewho isnotparticularlytall,Ihavealwaysfocusedon mystrengthsandcontributionsratherthanmy physicalappearance,”shesays.Shebelieves firmlyinthevaluethatwomenbringto decision-making,oftenquotingRuthBader Ginsburgontheimportanceofhavingwomenin anyroomwheredecisionsaremade.Women, shebelieves,approachchallengesdifferently, offeringuniqueinsightsthatleadtobetter,more collaborativeoutcomes.
ThisbeliefhasresultedinaworkforceatMAC Rxthatisremarkablydiverse.Miriamnotesthat theteamsfeelalmostglobalintheir composition,aresultnotofintentionalquotas, butofasimple,powerfulhiringphilosophy:hire thebestindividualswiththerightvalues,drive, andintentions.Byfocusingontalentand character,thecompanyhasbuiltanenvironment whereraceandgenderaresecondary,anda cultureoftrueinclusivityhasblossomed organically
Intheend,MiriamCho’sstoryisapowerful testamenttotheideathatthegreatest professionalsuccessesareoftenfueledbythe mostpersonalmotivations.Forher,itallcomes backtoherchildren,totheimmigrantdriveto buildabetterlife.“Forthosewhoknowme,it’s clearthatIoftentalkaboutmykids,”shesays. Byprioritizingherfamily,shehasfoundthe focusandgroundingtobuildathriving business.Heradvicetoaspiringwomen professionalsisareflectionofherown journey:takeboldandconfidentsteps.
“Theworstthatcanhappenissomeonetells you‘no,’“shesays,“butatleastyoucan sayyoutried.”Itisaphilosophythathas servedherwell,aleapoffaiththatturnedan unplanneddetourintoaremarkablejourneyto theforefrontofanindustry
DON’T MISS AN ISSUE
SCAN & GET INSPIRED, STAY UPDATED WITH ALL THE BUSINESS WORLD BUZZ WITH GLOBAL HEALTH CARE MAGAZINE
